In a nutshell
This study investigated the impact of the thyroid hormones (TH) on survival outcomes of patients with colorectal cancer treated with regorafenib (Stivarga). Researchers suggested that TH ratio can predict the outcomes in these patients.
TH such as FT3 (free triiodothyronine) and FT4 (free thyroxine) are released into the body from the thyroid gland. They have different roles, including cell growth. Prior studies showed that TH are associated with tumor growth and effectiveness of cancer treatments.
It has been shown that low levels of FT3 are associated with worse survival. Other studies showed that FT4 levels are associated with better physical condition and survival in the elderly. The role of the FT3/FT4 ratio as a predictive factor for patients with metastatic (spread to other parts of the body) colorectal cancer remains under investigation.
Methods & findings
This study included information about 73 patients with metastatic colorectal cancer treated with regorafenib. All patients had their levels of FT3 and FT4 measured before treatment. They were followed up for an average of 15.5 months.
The average overall survival in patients with low FT3/FT4 ratios was shorter (4.8 months) than in patients with high ratios (7.6 months). Patients with a high ratio had a 57% higher odds of having a better survival. High FT3/FT4 ratios were associated with a 41% higher chance of a better survival.
The bottom line
The study concluded that high ratios of TH are strongly associated with better outcomes in patients with advanced colorectal cancer treated with regorafenib.
The fine print
This study did not take into account conditions that may interfere with the levels of TH, such as liver impairment. Further, larger studies are needed for more conclusive results.
Published By :
Clinical Colorectal Cancer
Sep 01, 2018
If you sign up for Medivizor, you'll receive PERSONALIZED updates that are JUST FOR YOU. Want to give it a try?